Journal
BIOMATERIALS
Volume 83, Issue -, Pages 194-206Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2016.01.013
Keywords
Fibromodulin (FMOD); Reprogramming; Fibromodulin reprogrammed (FReP) cells; Differentiation; Osteogenesis
Funding
- UCLA and Orthopaedic Hospital Department of Orthopaedic Surgery
- Orthopaedic Hospital Research Center
- Eli & Edy Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Innovation Award
- National Center for Advancing Translational Sciences UCLA CTSI Grant [UL1TR000124]
- UCLA School of Dentistry
- Plastic Surgery Foundation [269698]
- NIH-NIDCR [R44DE024692]
- NIH-NIAMS [R44AR064126]
- International S&T Cooperation Program of China [2013DFB30360]
- NIH-NCRR shared resources grant [CJX1-443835-WS-29646]
- NSF Major Research Instrumentation grant [CHE-0722519]
Ask authors/readers for more resources
Pluripotent or multipotent cell -based therapeutics are vital for skeletal reconstruction in non-healing critical-sized defects since the local endogenous progenitor cells are not often adequate to restore tissue continuity or function. However, currently available cell -based regenerative strategies are hindered by numerous obstacles including inadequate cell availability, painful and invasive cell-harvesting procedures, and tumorigenesis. Previously, we established a novel platform technology for inducing a quiescent stem cell-like stage using only a single extracellular proteoglycan, fibromodulin (FMOD), circumventing gene transduction. In this study, we further purified and significantly increased the reprogramming rate of the yield multipotent FMOD reprogrammed (FReP) cells. We also exposed the 'molecular blueprint' of FReP cell osteogenic differentiation by gene profiling. Radiographic analysis showed that implantation of FReP cells into a critical -sized SCID mouse calvarial defect, contributed to the robust osteogenic capability of FReP cells in a challenging clinically relevant traumatic scenario in vivo. The persistence, engraftment, and osteogenesis of transplanted FReP cells without tumorigenesis in vivo were confirmed by histological and immunohistochemical staining. Taken together, we have provided an extended potency, safety, and molecular profile of FReP cell -based bone regeneration. Therefore, FReP cells present a high potential for cellular and gene therapy products for bone regeneration. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available